

## Genitourinary syndrome of menopause

OCTOBER 2018

In the article by A.C. Moreno, S.K. Sikka, and H.L. Thacker, Genitourinary syndrome of menopause in breast cancer survivors: Treatments are available, *Cleve Clin J Med* 2018; 85(10):760–766, doi:10.3949/

ccjm.85a.17108), **Table 2** incorrectly stated that prasterone is contraindicated in women with known or suspected breast cancer. This correction has been made online. The corrected table appears below:

TABLE 2

### FDA-approved labeling notes for treatments for genitourinary syndrome of menopause

| Products  | GSM indications  | Breast cancer effects   |
|---|--|---|
| <b>Estrogen products</b>  |  |   |
| 17-beta estradiol vaginal cream (Estrace)                               | Moderate to severe vulvar and vaginal atrophy due to menopause                             | All estrogen products have the following labeling notes:  |
| Conjugated estrogen vaginal cream (Premarin <sup>a</sup> )              | Moderate to severe dyspareunia due to menopause<br>Atrophic vaginitis and kraurosis vulvae | WHI: Estrogen alone was not associated with increased risk of breast cancer; estrogen plus progestin increased the risk<br>Contraindication: known, suspected, or history of breast cancer                                    |
| 17-beta estradiol vaginal ring (Estring)                                | Moderate to severe vulvar and vaginal atrophy due to menopause                             | Warning: Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration  |
| Estradiol hemihydrate vaginal tablets (Vagifem, Yuvaferm <sup>b</sup> ) | Atrophic vaginitis due to menopause  |   |
| Estradiol vaginal inserts (Imvexxy)                                     | GSM, dyspareunia   |   |
| <b>Combination estrogen product</b>                                     |  |   |
| Conjugated estrogens/bazedoxifene (Duavee)                              | Moderate to severe vasomotor symptoms associated with menopause                            |   |
| <b>Nonestrogen products</b>   |  |   |
| Prasterone vaginal tablet (Intrarosa; contains dehydro-epiandrosterone) | Moderate to severe dyspareunia due to menopause  | <b>Warning: Estrogen is a metabolite of prasterone; use of exogenous estrogen is contraindicated in women with known or suspected breast cancer; prasterone has not been studied in women with a history of breast cancer</b> |
| Ospemifene (Osphena) oral tablet  | Moderate to severe dyspareunia due to menopause  | Warning: Ospemifene has not been adequately studied in women with breast cancer; therefore, it should not be used in women with known or suspected breast cancer or with a history of breast cancer                           |

<sup>a</sup>Premarin vaginal cream is the only locally applied preparation with FDA approval for dyspareunia due to GSM.

<sup>b</sup>Yuvaferm is an FDA-approved generic equivalent to Vagifem.

FDA = US Food and Drug Administration; GSM = genitourinary syndrome of menopause; WHI = Women's Health Initiative study